Supplemental HIV Testing Market Woes Force FDA To Consider Other Options
This article was originally published in The Gray Sheet
The financial instability of Calypte Biomedical over the past several months has increased FDA's interest in licensing alternative approaches for confirmatory HIV testing for blood banks, including nucleic acid testing
You may also be interested in...
Calypte Biomedical's April announcement of possible bankruptcy triggers CDC's May 10 warning of potential U.S. shortage of supplemental tests kits for confirmatory testing of HIV antibodies in specimens derived from patients or blood donors. Distributor bioMérieux has notified customers of a halt in Cambridge Biotech HIV-1 Western blot kit shipments. CDC and FDA have contacted other HIV test-makers, including BioRad Laboratories and OraSure, about ramping up kit production. Labs experiencing shortage should contact CDC at 404-639-4581...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.